Role of glucagon-like peptide-1 (GLP-1) receptor agonists versus DPP-4 inhibitors for alcohol and substance use disorders in improving HIV-related outcomes and providing health benefits in people…
Active Purchase Order Awarded Last action
- Contract number
- 75N98026P01298
- Awardee
-
Yale Univ UEI FL6GV84CKN57
- Awarding agency
-
Office of Logisitics and Acquisition Operations
National Institutes of Health, Department of Health and Human Services
- Obligated
- $251,752
Award facts
- Opportunity
-
- Role of Glucagon-like Peptide-1 (GLP-1) receptor agonists versus DPP-4 inhibitors for alcohol and substance use disorders in improving HIV-related outcomes and providing health benefits in people living with HIV Pre-Solicitation · 75N95026R00007 · Posted Apr 22, 2026
- Contract value 25% obligated
-
- $251,751.97 Current, with exercised options
- $1,007,007.88 Potential, with all options
- Completion date 4% complete
-
- Current, with exercised options
- Potential, with all options
- Funding agency
- National Institute on Drug Abuse National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541690 Other Scientific and Technical Consulting Services
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- New Haven, CT 06520, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this award
The National Institute on Drug Abuse issued a purchase order to Yale University on August 24, 2026, for pharmacoepidemiological research services valued at $1,007,007.88. Work is performed in New Haven, Connecticut, and involves data extraction, management, analysis, and reporting for a propensity-score matched study examining the efficacy of Glucagon-like Peptide-1 (GLP-1) receptor agonists versus DPP-4 inhibitors in improving HIV-related outcomes for people living with HIV with comorbid alcohol and substance use disorders. The study utilizes Veterans Aging Cohort Study data from the Department of Veterans Affairs spanning 20 or more years of longitudinal Veterans Health Administration records. The order is classified under NAICS 541690 and PSC B529. Period of performance extends to August 23, 2030, with an initial 12-month base period and three optional 12-month extension periods.
Description
Role of glucagon-like peptide-1 (GLP-1) receptor agonists versus DPP-4 inhibitors for alcohol and substance use disorders in improving HIV-related outcomes and providing health benefits in people living with HIV
Quick answers
Who was awarded contract 75N98026P01298?
75N98026P01298 was awarded to Yale Univ by Office of Logisitics and Acquisition Operations (National Institutes of Health) on August 24, 2026.
How much is contract 75N98026P01298 worth?
The government has obligated $251,752 on 75N98026P01298. Its potential value, with all options, is $1,007,008.
Which agency awarded contract 75N98026P01298?
Office of Logisitics and Acquisition Operations (National Institutes of Health) awarded 75N98026P01298, with funding from National Institute on Drug Abuse (National Institutes of Health).
Was contract 75N98026P01298 competed?
The extent of competition for 75N98026P01298 was competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award